Search Results
Jun 03, 2026, 09:43 ET ЕВРОПЕЙСКАЯ КОМИССИЯ ОДОБРИЛА ПРЕПАРАТ AMGEN IMDYLLTRA® ДЛЯ ЛЕЧЕНИЯ МЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКОГО НА ЗАПУЩЕННОЙ СТАДИИ
препараты до и после инфузий IMDELLTRA® в день 1 цикла 1 и день 8 цикла 1, как описано в Таблице 3 Инструкции по медицинскому применению (PI). Вводите IMDELLTRA® в соответствующем медицинском учреждении, оборудованном для мониторинга и лечения CRS. Перед введением IMDELLTRA®
More news about: Amgen
Jun 03, 2026, 09:27 ET LA CE APRUEBA IMDYLLTRA® DE AMGEN PARA EL CÁNCER DE PULMÓN DE CÉLULAS PEQUEÑAS EN ESTADIO AVANZADO
recomendados antes y después de las infusiones de IMDELLTRA® del día 1 y del día 8 del ciclo 1 para reducir el riesgo de reacciones SLC como se describe en el PI (Tabla 3).IMDELLTRA® solo debe ser administrado por un profesional de la salud calificado con el apoyo médico apropiado
More news about: Amgen
Jun 02, 2026, 14:18 ET The Inner Circle acknowledges Ashley "Ash" Spoto, M.Ed as a Pinnacle Professional of The Year
at Susquehanna University and supports philanthropic initiatives as an advisor and Friend of Beta Ambassador and fundraising supporter for Beta Theta Pi.In her personal time, Ms. Spoto enjoys hiking, reading, travel, and spending time with friends and family. Looking ahead, she remains focused on
More news about: The Inner Circle
Jun 02, 2026, 10:23 ET Stelexis BioSciences Announces Positive Phase 1 Data for Eganelisib in Relapsed/Refractory AML and Higher-Risk MDS in an Oral Presentation at ASCO 2026
treatment-naïve, PI3K-gamma-high MDS patients with an IPSS-R category of intermediate, high, or very-high risk or with CMML-2.About EganelisibEganelisib is a first-in-class, oral, highly potent, and isoform-selective inhibitor of PI3K-gamma, the myeloid-restricted isoform of the PI3K kinase
More news about: Stelexis BioSciences, Inc.
Jun 02, 2026, 08:13 ET High-Force Ceramic Motor Linear Actuator Achieves Sub-Nanometer Precision
radiation-sensitive environments.SHREWSBURY, Mass., June 2, 2026 /PRNewswire/ -- PI, a global leader in precision motion control and nanopositioning, offers a broad range of piezo ceramic linear actuators for demanding motion applications.
More news about: Physik Instrumente (PI)
Jun 02, 2026, 08:00 ET RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
target—SPHK2 inhibition—disrupts host-cell components essential for filovirus entry and replication that are conserved across FiloviridaePI3K/Akt pathway inhibition (required for filovirus entry and membrane trafficking)NLRP3 and IL-6/TNFα inflammasome suppression and S1P-mediated
More news about: RedHill Biopharma Ltd.
Jun 02, 2026, 07:30 ET Kazia Therapeutics Appoints James Levine as Chief Financial Officer
oncology-focused drug development company, based in Sydney, Australia. The Company's lead asset, paxalisib, is an investigational brain penetrant inhibitor of the PI3K/Akt /mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject
More news about: Kazia Therapeutics Limited
Jun 02, 2026, 01:46 ET TOMY將推出首款配備Gravity Cannon的Ultrasaurus模型：ZOIDS「AZ-17DX ULTRA SAURUS GRAVITY CANNON Ver.」定於2027年2月下旬發售
https://cdn.kyodonewsprwire.jp/prwfile/release/M000076/202605259631/_prw_PI1fl_rUOGIepg.jpgUltrasaurus是一款巨型恐龍機體，自1986年首次推出以來，一直是ZOIDS品牌中的經典形象。在ZOIDS原創動畫（1999-2000年）中，它因其動畫原創武器Gravity Cannon而備受矚目。AZ-17DX
More news about: TOMY Company, Ltd.
Jun 01, 2026, 16:00 ET EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
medications before and after Cycle 1 Day 1 and Cycle 1 Day 8 IMDELLTRA® infusions as described in Table 3 of the Prescribing Information (PI) to reduce the risk of CRS. Administer IMDELLTRA® in an appropriate healthcare facility equipped to monitor and manage CRS. Ensure patients
More news about: Amgen
Jun 01, 2026, 10:00 ET LawPro.ai Co-Founder Releases "I'm the Pro: Here's the Proof," A Practitioner's Playbook for the AI-Driven Future of Personal Injury Law
typewriters to PCs, and that the window to adapt is closing faster than most owners think. Private equity is rolling up PI markets. AI-native firms are emerging. And while 92% of PI firms now report using AI, 56% spend $5,000 or less on it annually, according to the Future of Legal Tech 2026 report
More news about: LawPro.ai Inc.
May 30, 2026, 15:25 ET Menarini Group 於 2026 年美國臨床腫瘤學會 (ASCO) 週年大會上發表第 1b/2 期 ELEVATE 研究中，使用埃拉司群 (Elacestrant) 聯合卡帕塞替尼 (Capivasertib) 治療 ER+、HER2- 轉移性乳癌 (mBC) 患者的最新數據。
轉移性乳癌中觀察到的不同抗藥性機制，並且在不論 ESR1 突變狀態如何的情況下，提升患者治療成果。 研究包含六種治療方案，分別評估埃拉司群與 CDK4/6 抑制劑（帕博西尼 (palbociclib)、阿貝馬西利 (abemaciclib) 及瑞博西利 (ribociclib)），以及 PI3K/AKT/mTOR 訊號傳導途徑抑制劑（依維莫司 (everolimus)、阿培利西 (alpelisib) 和卡帕塞替尼 (capivasertib)）聯合治療的療效。2026 年美國臨床腫瘤學會週年大會上公佈的 ELEVATE 研究結果（摘要 1098）[1]
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 09:09 ET Il Gruppo Menarini presenta nuovi dati dello studio ELEVATE di fase 1b/2 su elacestrant in combinazione con capivasertib in pazienti con carcinoma mammario metastatico (mBC) ER+, HER2- in occasione del Congresso annuale 2026 dell'American Society of Clinical Oncology (ASCO)
regimi terapeutici che valutano elacestrant in combinazione con inibitori di CDK4/6 (palbociclib, abemaciclib e ribociclib) e con inibitori della via PI3K/AKT/mTOR (everolimus, alpelisib e capivasertib).I risultati dello studio ELEVATE presentati all'ASCO 2026 (abstract 1098) [1] includono
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 09:07 ET Menarini Group apresenta novos dados do estudo ELEVATE de Fase 1b/2 sobre o elacestranto em associação com o capivasertibe em pacientes com câncer de mama metastático (CMm) ER+, HER2- no Congresso Anual de 2026 da American Society of Clinical Oncology (ASCO)
regimes de tratamento que avaliam o elacestranto em combinação com inibidores de CDK4/6 (palbociclibe, abemaciclibe e ribociclibe) e com inibidores da via PI3K/AKT/mTOR (everolimo, alpelisibe e capivasertibe).Resultados do estudo ELEVATE apresentados na ASCO 2026 (resumo 1098) [1] incluem
More news about: Menarini Industrie Farmaceutiche Riunite
May 30, 2026, 09:02 ET Menarini Group presenta nuevos datos del ensayo ELEVATE de fase 1b/2 de elacestrant combinado con capivasertib en pacientes con cáncer de mama metastásico (CMM) con receptores de estrógeno positivos (ER+) y HER2 negativo (HER2-) en la reunión anual de la Sociedad Estadounidense de Oncología Clínica (ASCO) de 2026
regímenes de tratamiento que evalúan el elacestrant combinado con inhibidores de CDK4/6 (palbociclib, abemaciclib y ribociclib) y con inhibidores de la vía PI3K/AKT/mTOR (everolimus, alpelisib y capivasertib).Los resultados de ELEVATE que se presentaron en la ASCO 2026 (resumen 1098)[1] incluyen
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 17:06 ET Die Menarini Group präsentiert auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO) neue Daten aus der Phase-1b/2-Studie ELEVATE zu Elacestrant in Kombination mit Capivasertib bei Patientinnen mit ER-positivem, HER2-negativem metastasiertem Brustkrebs (mBC)
sechs Behandlungsschemata, in denen Elacestrant in Kombination mit CDK4/6-Inhibitoren (Palbociclib, Abemaciclib und Ribociclib) sowie mit Inhibitoren des PI3K/AKT/mTOR-Signalwegs (Everolimus, Alpelisib und Capivasertib) untersucht wird.Die auf der ASCO 2026 vorgestellten ELEVATE-Ergebnisse (Abstract
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 11:40 ET Le Groupe Menarini présente de nouvelles données de l'étude ELEVATE sur l'association de l'élacestrant et du capivasertib
thérapeutiques évaluant l'élacestrant en association avec des inhibiteurs de CDK4/6 (palbociclib, abémaciclib et ribociclib) et avec des inhibiteurs de la voie PI3K/AKT/mTOR (évérolimus, alpelisib et capivasertib).Les résultats d'ELEVATE présentés à l'ASCO 2026 (résumé 1098)[1] comprennent les
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 10:13 ET 메나리니 그룹, 2026 미국임상종양학회(ASCO) 연례회의에서 ER+, HER2- 전이성 유방암(mBC) 환자를 대상으로 엘라세스트란트와 카피바서팁 병용요법을 평가한 1b/2상 ELEVATE 시험 신규 데이터 발표
관찰되는 다양한 내성 기전을 극복하고 ESR1 돌연변이 상태와 관계없이 환자 예후를 개선하기 위해 엘라세스트란트 병용 투여 옵션의 안전성과 유효성을 평가하도록 설계됐다. 이 시험은 엘라세스트란트를 CDK4/6 억제제(팔보시클립, 아베마시클립 및 리보시클립), PI3K/AKT/mTOR 경로 억제제(에베로리무스, 알펠리십 및 카피바서팁)와 각각 병용 평가하는 6개 치료 요법으로 구성돼 있다.ASCO 2026에서 보고되는 ELEVATE 결과(초록 1098)[1]에는 제1b상 엘라세스트란트(258~345mg)와 카피바서팁(320~400mg)
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 10:04 ET Arasan Chip Systems annonce la première solution IP Sureboot™ Total 16 bits xSPI + PSRAM.
des années 90 aux automobiles, drones et appareils IdO d'aujourd'hui. Arasan reste à l'avant-garde de cette évolution « mobile », en fournissant une PI basée sur des normes qui constitue la base des systèmes sur puce mobiles. Plus d'un milliard de puces ont été expédiées avec l'IP d'Arasan.A
More news about: Arasan Chip Systems, Inc.
May 29, 2026, 08:18 ET New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
prior therapyAs monotherapy in patients who have received at least three prior lines of therapy including a PI and an immunomodulatory agent or who are double refractory to a PI and an immunomodulatory agentDARZALEX FASPRO® as monotherapy is indicated for the treatment
More news about: Johnson & Johnson
May 29, 2026, 08:15 ET Xtep Recognized for Leading Position in the global running shoes market in 2025 as Industry Advances Toward Professionalization and Scenario Segmentation
elastic underfoot feel to help runners accelerate; and Xtep's proprietary XTEP POWER Technology Matrix, which innovatively applies aerospace-grade PI fibers and basalt fibers to running shoes, effectively resolving the industry pain point of carbon fiber brittleness and fracture, thereby providing
More news about: Xtep
May 29, 2026, 05:23 ET Menarini Group presenta nuevos datos del estudio ELEVATE de elacestrant en combinación con capivasertib
regímenes de tratamiento que evalúan elacestrant en combinación con inhibidores de CDK4/6 (palbociclib, abemaciclib y ribociclib) y con inhibidores de la vía PI3K/AKT/mTOR (everolimus, alpelisib y capivasertib).Los resultados de ELEVATE presentados en ASCO 2026 (resumen 1098)[1] incluyen datos de seguridad
More news about: Menarini Industrie Farmaceutiche Riunite
May 29, 2026, 02:00 ET TOMY to Launch First Ultrasaurus Model Featuring Gravity Cannon: ZOIDS "AZ-17DX ULTRA SAURUS GRAVITY CANNON Ver." Set for Late February 2027 Release
https://cdn.kyodonewsprwire.jp/prwfile/release/M000076/202605259631/_prw_PI1fl_rUOGIepg.jpgUltrasaurus, a massive dinosaur first released in 1986, remains an iconic presence within the ZOIDS
More news about: TOMY Company, Ltd.
May 28, 2026, 12:46 ET Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
treatment regimens evaluating elacestrant in combination with CDK4/6 inhibitors (palbociclib, abemaciclib and ribociclib) and with inhibitors of the PI3K/AKT/mTOR pathway (everolimus, alpelisib and capivasertib).ELEVATE results reported at ASCO 2026 (abstract 1098)[1] include safety
More news about: Menarini Industrie Farmaceutiche Riunite
May 28, 2026, 06:00 ET Piezoelectric Ceramics Market worth $2.10 billion in 2031 - Exclusive Report by MarketsandMarkets™
Corporation (Japan), CeramTec GmbH (Germany), CTS Corporation (US), Murata Manufacturing Co., Ltd. (Japan), TDK Corporation (Japan), Physik Instrumente (PI) GmbH & Co. (Germany), APC International, Ltd. (US), L3Harris Technologies, Inc. (US), Meggitt PLC (UK), Piezo Technologies (US), and Tayca Corporation
More news about: MarketsandMarkets
May 28, 2026, 00:15 ET ZOTAC to Celebrate 20th Anniversary with Full-Spectrum Showcases, and Anniversary-Exclusive Hardware
SoC-powered AIPCs, embedded MXM GPU modules, as well as the ZBOX PRO PICO-CM5, currently the world's most feature-dense compute module powered by the Raspberry Pi CM5.Additionally, ZBOX PRO solutions powered by the latest NVIDIA Jetson T5000 system-on-module will also be shown, which feature NVIDIA Blackwell
More news about: ZOTAC Technology Pte. Limited